Drugs / Recombinant LH

Trials 3 · a red edge is where a trial was stopped

201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 42 trials
Phase 4 NCT01500863 Nov 2011 → May 2012 ovarian hyperstimulation syndrome IVI Madrid Completed No outcome recorded
Phase 4 NCT01936077 Jun 2010 → May 2013 infertility disorder Assuta Hospital Systems Completed No outcome recorded
Phase not applicable1 trial
NCT01457703 Jun 2010 → Jul 2013 obesity disorder University of Colorado, Denver Completed No outcome recorded
Also used as a comparator or background therapy in 3 trials
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 21 trial
Phase 2 NCT06883890 Comparator Mar → Nov 2025 overdue ovarian disorder University Hospital of Modena Not yet recruiting No outcome recorded
Phase 41 trial
Phase 4 NCT07121751 Comparator Sep 2025 → Aug 2026 overdue infertility disorder Dunamenti REK Istenhegyi IVF Center Not yet recruiting No outcome recorded
Phase not applicable1 trial
NCT02244866 Comparator Oct 2012 → Apr 2014 infertility disorder Vietnam National University Completed No outcome recorded

Evidence & citations 6 cited values

Every value below carries the sentence it was read from. 7 sources stand behind the page.

FieldValueCited text
Known as recombinant LH “150 IU of recombinant FSH and 75 IU of recombinant LH (Pergoveris) daily subcutaneous injection” NCT02244866
5

NCT01936077

NCT07121751

NCT01500863

NCT06883890

NCT01457703

Known as Luveris “Drug: Recombinant LH (Luveris)” NCT06883890
Known as rLH “In the treatment group patients will receive the pretreatment with rLH, a daily dose of 187.5 IU (75 U in the morning and 112.5U in the evening) rLH treatment for 60 days will...” NCT06883890
Action Activate “Used to stimulate ovarian function in women.” NCT01457703
Modality Protein / enzyme biologic “recombinant luteinizing hormone” PMID 25740882 Mar 2015
Route Subcutaneous “150 IU of recombinant FSH and 75 IU of recombinant LH (Pergoveris) daily subcutaneous injection” NCT02244866